Uveal Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q3 2027.
Clinical MilestonesViewHide
- 2026-06-01ClinicalA Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Uveal MelanomaResults expected Q3 2027
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Melanoma4
- Uveal Neoplasms4
- Antineoplastic Combined Chemotherapy Protocols1
- Choroid Neoplasms1
- Circulating Tumor DNA1
- DNA Methylation1
- Gene Expression Regulation, Neoplastic1
- Immune Checkpoint Inhibitors1
Leading journals6
- The New England journal of medicine2
- Cancer1
- Cancer cell1
- Frontiers in immunology1
- Nature communications1
- Ophthalmology1
Leading researchers8
- Hassel JC3
- Piperno-Neumann S3
- Baurain JF2
- Butler MO2
- Carvajal RD2
- Coupland SE2
- Curti B2
- Demidov L2
Affiliations (unnormalised)6
- Institut Curie2
- University Hospital Essen2
- Bavarian Cancer Research Center (BZKF)1
- Buck Institute for Research on Aging1
- Canada's Michael Smith Genome Sciences Centre1
- Center for Biomolecular Sciences and Engineering1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Uveal neoplasms are tumors or cancers arising in the uvea, the vascular layer of the eye. The term covers malignant disease of this ocular structure and includes primary tumors as well as secondary involvement.
The supplied grounding does not identify a specific cause or aetiology for uveal neoplasms. It does indicate that secondary disease is discussed, implying that some cases represent spread from another cancer rather than a primary uveal origin.
The literature grounding indicates pathology, immunology, blood, and genetics as covered aspects, suggesting that uveal neoplasms are studied in terms of tumor biology, immune features, hematologic findings, and genetic alterations. No specific mechanistic pathway is provided in the supplied material.
The supplied grounding does not support specific risk factors for uveal neoplasms.
The supplied grounding supports drug therapy and identifies tebentafusp as a co-studied agent, placing treatment within systemic drug-based therapy. The presence of recombinant fusion proteins in the grounding is consistent with biologic or immunotherapeutic modalities, but no broader standard regimen is specified.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancer of the UVEA.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.